The effect of probiotic bacteria and pharmacological anti-inflammatory effects on the size of myocardial infarction in rats with systemic inflammation
- 31 May 2025
- journal article
- Published by ECO-Vector LLC in Medical academic journal
- Vol. 25 (1) , 42-53
Abstract
BACKGROUND: In recent years, it has been shown that certain probiotics have a cardioprotective effect in conditions of comorbidity and systemic inflammation. The mechanisms of probiotic-mediated cardioprotection have not been studied in practice. There is an assumption that the heart attack-limiting effect of probiotics is mediated by their anti-inflammatory effect. AIM: To study the severity of the cardioprotective effect of a mixture of probiotic strains of Lactobacillus acidophilus (LA-5) and Bifidobacterium animalis subsp. lactis (BB-12) in rats with systemic inflammatory response syndrome in comparison with the use of IL-1 receptor blockers, AT1 angiotensin II receptors, M-cholinergic receptors, as well as an inhibitor of tumor necrosis factor alfa binding to its receptors. METHODS: The experiments were performed on male Wistar stock rats on a model of systemic inflammatory response syndrome. The rats of the corresponding groups, after chemical induction of a systemic inflammatory response, were intragastrically injected with probiotic strains, losartan and hyoscine butyl bromide; subcutaneously — etanercept and anakinra for 8 days. The assessment of myocardial resistance to ischemic-reperfusion injury was carried out on the model of global ischemia-reperfusion of an isolated heart at an upgraded Langendorff facility, by planimetric estimation of the size of the necrosis zone. The concentration of cytokines in blood plasma was assessed by enzyme immunoassay. RESULTS: The size of the myocardial necrosis zone in the systemic inflammatory response group, rats with systemic inflammatory response syndrome, was significantly higher than in the control group — 45% (38; 48)% and 30% (26; 31)% (p 0.05). In the groups of probiotic strains, anakinra and losartan, the size of the necrosis zone was 32% (28; 35)%, 26% (24; 35)% and 30% (25; 36)%, which is less than in the systemic inflammatory response group (p 0.05). In the etanercept and hyoscine butyl bromide groups, the size of the necrosis zone was 35% (26; 36)% and 42% (32; 46)%, not significantly different from the SIR group (p 0.05). Hemodynamic parameters of the isolated heart did not differ between the groups. In the systemic inflammatory response group, the concentration of proinflammatory cytokines and transforming growth factor beta in blood plasma was significantly higher than in the control group. At the same time, in the groups of probiotic strains, anakinra, losartan and hyoscine butyl bromide, a significant decrease in the levels of certain cytokines was noted, confirming the presence of an anti-inflammatory effect. CONCLUSION: The introduction of probiotics to rats with systemic inflammatory response syndrome caused a decrease in the size of the necrosis zone. At the same time, the blockade of tumor necrosis factor alfa binding to receptors and the blockade of M-cholinergic receptors were not accompanied by a decrease in size of the necrosis zone in this model. Pharmacological blockade of the IL-1 and AT1 angiotensin II receptors had a cardioprotective and anti-inflammatory effect similar to the probiotic strains group, which indicates the unidirectional effect of the tested effects.Keywords
This publication has 32 references indexed in Scilit:
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019JACC, 2020
- Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart FailureCardiovascular Drugs and Therapy, 2020
- Recombinant human interleukin-1 receptor antagonist treatment protects rats from myocardial ischemia–reperfusion injuryBiomedicine & Pharmacotherapy, 2019
- Reduced acute myocardial ischemia–reperfusion injury in IL-6-deficient mice employing a closed-chest modelInflammation Research, 2016
- Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the MouseCardiovascular Drugs and Therapy, 2012
- Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia–reperfusion induced infarct sizeCytokine, 2011
- Peak Cardiac Troponin-T Level, Scintigraphic Myocardial Infarct Size and One-Year Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial InfarctionThe American Journal of Cardiology, 2010
- Free radicals trigger TNF?-induced cardioprotectionCardiovascular Research, 2005
- Influence of the angiotensin II AT 1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heartBasic Research in Cardiology, 2000
- The effects of the pharmacological manipulation of postoperative intestinal motility on colonic anastomosesInternational Journal of Colorectal Disease, 1997